Loading...
XKRX084990
Market cap81mUSD
Jan 09, Last price  
2,850.00KRW
1D
-0.87%
1Q
-16.54%
Jan 2017
-97.25%
IPO
-94.07%
Name

Helixmith Co Ltd

Chart & Performance

D1W1MN
XKRX:084990 chart
P/E
—
P/S
28.18
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
6.87%
Rev. gr., 5y
6.09%
Revenues
4.20b
+50.08%
3,888,130,9305,745,711,9307,695,186,3106,844,031,5243,157,908,5933,127,118,8004,454,515,6034,248,298,8802,316,243,8552,799,607,4744,201,622,670
Net income
-64.09b
L+47.20%
-4,632,642,230265,714,850256,981,384-714,455,753-6,495,715,322-28,728,935,734-107,036,905,258-82,856,513,815-70,217,907,873-43,538,298,147-64,088,431,010
CFO
-23.64b
L-39.35%
-3,581,993,09011,221,8601,211,270,408-2,384,987,881-1,502,924,112-11,968,544,493-37,540,204,732-41,138,567,807-36,755,053,910-38,971,587,142-23,637,987,786
Dividend
Mar 15, 20220.285 KRW/sh
Earnings
Feb 12, 2025

Profile

Helixmith Co., Ltd, a biotechnology company, discovers and develops biopharmaceuticals for human diseases. The company has a pipeline of novel biologics and herbal therapeutics in the areas of cardiovascular disease, cancer, and immune disorder, with clinical studies ongoing in the United States, Korea, and China. Its flagship product is VM202, a DNA-based drug for cardiovascular and neurological diseases. The company's pipeline products include VM206, a therapeutic cancer vaccine targeting HER2/neu positive breast or ovarian cancer; and VM501, a re-engineered form of interleukin 11 targeting chemotherapy-induced thrombocytopenia. Its clinical trials biologics comprise VM202-DPN, VM202-PAD, VM501, VM202-ALS, VM202-CAD, and VM206. The company was formerly known as ViroMed Co., Ltd. and changed its name to Helixmith Co., Ltd in April 2019. Helixmith Co., Ltd was incorporated in 1996 and is headquartered in Seoul, South Korea.
URL
http://helixmith.com/
IPO date
Dec 29, 2005
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
4,201,623
50.08%
2,799,607
20.87%
Cost of revenue
30,165,726
44,075,594
Unusual Expense (Income)
NOPBT
(25,964,104)
(41,275,986)
NOPBT Margin
Operating Taxes
(100,017)
57,453
Tax Rate
NOPAT
(25,864,087)
(41,333,439)
Net income
(64,088,431)
47.20%
(43,538,298)
-38.00%
Dividends
Dividend yield
Proceeds from repurchase of equity
46,575,343
34,653,976
BB yield
-18.18%
-8.70%
Debt
Debt current
20,016,595
20,000,000
Long-term debt
287,165
570,797
Deferred revenue
Other long-term liabilities
1,747,016
3,816,562
Net debt
(107,662,213)
(84,509,313)
Cash flow
Cash from operating activities
(23,637,988)
(38,971,587)
CAPEX
(254,870)
(7,636,101)
Cash from investing activities
(17,018,992)
25,483,810
Cash from financing activities
40,919,599
16,027,073
FCF
31,586,472
7,230,824
Balance
Cash
113,976,496
61,075,724
Long term investments
13,989,478
44,004,387
Excess cash
127,755,892
104,940,130
Stockholders' equity
(472,852,609)
(367,777,706)
Invested Capital
648,549,098
608,643,341
ROIC
ROCE
EV
Common stock shares outstanding
41,514
37,736
Price
6,170.00
-41.52%
10,550.00
-53.52%
Market cap
256,144,372
-35.66%
398,118,556
-53.43%
EV
148,067,748
313,286,811
EBITDA
(15,269,990)
(30,831,559)
EV/EBITDA
Interest
582,441
2,075,280
Interest/NOPBT